[
  {
    "chunk_id": 0,
    "start": "00:00:00.000",
    "end": "00:01:21.757",
    "audio_caption": "The audio begins with suspenseful, dramatic music that creates a sense of mystery and anticipation. A single female speaker then takes over in a confident and professional tone, recounting her professional journey. She discusses moving into sales, research and development, marketing, becoming a board member, managing a business, and various roles in Europe and the US. She mentions looking after a region, becoming a sponsor of a sustainability group, chairing a corporate citizens' trust, and being an advisory member of a women's leadership panel. She concludes by expressing her love for her job, conveying her enthusiasm. The suspenseful music then returns, drawing the audio to a close."
  },
  {
    "chunk_id": 1,
    "start": "00:01:21.757",
    "end": "00:02:25.628",
    "audio_caption": "The clip features a female speaker discussing Johnson's recent collaborations and innovation centers in locations like California, Boston, and London. She mentions the aim of fostering collaboration between small biotech, universities, and research establishments, with a mantra of following great science wherever it is. She then discusses the industry's openness to collaboration, sharing of science, particularly in areas like Alzheimer's, acknowledging it as a tricky subject to innovate in."
  },
  {
    "chunk_id": 2,
    "start": "00:02:25.628",
    "end": "00:03:26.797",
    "audio_caption": "A woman is speaking in a measured, articulate tone, emphasizing the need for the industry to \"demonstrate value for money\" and suggesting a move towards \"common HTA assessment,\" contrasting it with a common pricing framework. She mentions that countries will differ in pricing but need to assess drugs the same way, mentioning Germany's toughness on comparators. Subsequently, the same woman notes that they have been discussing \"transparency of doctor payments\" and \"transparency of clinical trials data.\""
  },
  {
    "chunk_id": 3,
    "start": "00:03:26.797",
    "end": "00:03:48.453",
    "audio_caption": "A female speaker begins, discussing doctor payments and data transparency, stating that there will be transparency on the former and more news coming out in the future. She says the industry understands the general public's requirement for transparency on data, and they are making progress."
  },
  {
    "chunk_id": 4,
    "start": "00:03:48.453",
    "end": "00:04:15.394",
    "audio_caption": "The clip features a single female speaker discussing a company's transparency policy and the need for industry-wide progress on the topic. She mentions their policy is \"clear about what our transparency policy is right now\" and discusses \"coalescing of the industry\" to improve, because withholding information impedes trust. The speaker concludes by emphasizing that increased transparency \"can be made the better.\" Her tone is professional and thoughtful."
  },
  {
    "chunk_id": 5,
    "start": "00:04:15.394",
    "end": "00:05:08.202",
    "audio_caption": "The audio clip features one speaker, who is female, discussing clinical research and protocol transparency. She mentions that protocols are \"lodged on a website clinicaltrials.gov\" and that clinical research programs will \"ultimately be public\" after product approval. She sounds positive and confident. She emphasizes the importance of transparency, while also considering commercial and competitive aspects. She expresses optimism that the industry will commit to more transparency and break down barriers."
  },
  {
    "chunk_id": 6,
    "start": "00:05:08.202",
    "end": "00:05:25.448",
    "audio_caption": "A female speaker describes a spectrum of ongoing activities, emphasizing health literacy and education, delivered in an informative tone."
  },
  {
    "chunk_id": 7,
    "start": "00:05:25.448",
    "end": "00:06:27.683",
    "audio_caption": "The clip features one female speaker, who begins by explaining the concept of not merely investing money in projects, but rather, empowering communities and societies. She continues to describe how they facilitate the development of healthcare infrastructure and the delivery of improved healthcare. She then references their access activities, particularly in the context of HIV, where they have waived their IP rights on Duronavier in Africa to facilitate easier manufacturing, improving access. She ends by stating that such actions are driven by a sense of social responsibility on behalf of corporations, such as J and J."
  },
  {
    "chunk_id": 8,
    "start": "00:06:27.683",
    "end": "00:07:07.061",
    "audio_caption": "The clip begins with a female speaker offering advice, saying, \"don't underestimate what you can do.\" She notes that many young women aren't confident in their abilities, which can hold them back. She adds that she'd like to tell people like herself starting off a career to be confident and not to underestimate their potential. The sound of mellow music transitions in after the woman finishes speaking, and the clip ends with this quiet ambient music."
  }
]